LYNPARZA® Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer Life Science Investing
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results Pharmaceutical Investing
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights Pharmaceutical Investing
Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution for Real-Time Cryo-EM Data Analysis Medical Device Investing
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx for Treatment of Acute Myocarditis Pharmaceutical Investing
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® Plus LENVIMA® Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Life Science Investing
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Life Science Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
